For the first time, medical researchers will study the acute effects of cannabis on cognition in bipolar
Different doses of Epidiolex (CBD) and THC (Dronabinol) will be evaluated and compared to placebo.
“Contrary to reports among non-psychiatric patients, cannabis may improve cognition among people with bipolar disorder.”
The clinical trial is currently in the recruiting phase and expected to be completed by early 2023.
The research will be conducted at the University of California.